Published in Biotech Business Week, November 29th, 2004
The company has reported a 15% increase in Profit after Tax (PAT) to $47.4 million as compared to $41 million in the previous year for Q2. Net sales for the quarter has boosted by 12% to $282.6 million.
In its meeting dated October 30, 2004, the board approved issue of Foreign Currency Convertible Bonds (FCCB) or Equity (through GDR/ADR) of $50 million with a green shoe option of 15%. Given the issue's demand, higher sales are expected in the market.
The company has also finalized credit...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.